US/UK/Canada

Share

Contacts

  • Linda Wakeham

    Head of Marketing & Communication


    Kungsgatan 8, Stockholm
    +46 730 28 30 30
    http://mavatar.com

    • Links

    Quotes

    Initial exploration of Mavatar Discovery has identified biological signals that could be highly relevant to our current Alzheimer’s research identifying new targets.
    Tomas Deierborg, Professor of Experimental Medical Science at Lund University
    This collaboration demonstrates the value of combining clinical expertise with structured, data-driven resources. It’s encouraging to see how these tools are already informing research and opening new possibilities for more precise and effective IBD care.
    Dr. Ann-Sofie Backman, Associate Professor at Karolinska Institutet and Attending Physician in the Gastroenterology Unit at Ersta Hospital.
    Alongside our broader efforts to engage the life science community around data-driven precision medicine, we also want to lower barriers to advanced analytics in areas of high unmet need.
    Danuta Gawel, Chief Research & Development Officer at Mavatar
    We are pleased to collaborate with Sobi, whose deep commitment to rare diseases aligns strongly with our mission. Through advanced analytics of public transcriptomic data, we aim to contribute to a clearer understanding of IFNγ-driven mechanisms across relevant biological contexts.
    Johan Juhlin, CEO and Co-founder of Mavatar.
    Scientists no longer need to spend months cleaning datasets or building complex pipelines. With Mavatar Discovery, they can explore disease mechanisms, identify biomarkers, and generate pilot data in minutes - all without writing a single line of code.
    Johan Juhlin, CEO and Co-Founder of Mavatar
    We are very pleased to welcome Ulrika to Mavatar. Her extensive experience and broad network within Life Science make her a key part of our efforts to build strong partnerships and to further establish Mavatar in both the Nordic and global markets
    Johan Juhlin, CEO & Co-founder Mavatar
    Mavatar’s technology is a game-changer for drug development and personalized healthcare.
    Linda Wakeham
    "This investment brings us closer to revolutionizing global healthcare with personalized medicine."
    Johan Juhlin, CEO at Mavatar
    Pick a time period -
    Tags ( Active)
    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media